ACADIA PHARMACEUTICALS INC. Retained Earnings
ACADIA PHARMACEUTICALS INC. (ACAD) had Retained Earnings of -$1.78 billion as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$1.78B.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$1.81B.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$1.81B.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$2.09B.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$1.78B 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$1.81B 10-Q · filed 2026-05-07 |
| 2025-12-31 | -$1.81B 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$2.09B 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$2.16B 10-Q · filed 2025-08-07 |
| 2025-03-31 | -$2.19B 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$2.20B 10-K · filed 2026-02-26 |
| 2024-09-30 | -$2.35B 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$2.38B 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$2.41B 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$2.43B 10-K · filed 2025-02-27 |
| 2023-09-30 | -$2.48B 10-Q · filed 2023-11-03 |
| 2023-06-30 | -$2.41B 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$2.41B 10-Q · filed 2023-05-08 |
| 2022-12-31 | -$2.37B 10-K · filed 2024-02-28 |
| 2022-09-30 | -$2.33B 10-Q · filed 2022-11-03 |
| 2022-06-30 | -$2.30B 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$2.27B 10-Q · filed 2022-05-05 |
| 2021-12-31 | -$2.15B 10-K · filed 2023-02-28 |
| 2021-09-30 | -$2.11B 10-Q · filed 2021-11-09 |
| 2021-06-30 | -$2.10B 10-Q · filed 2021-08-05 |
| 2021-03-31 | -$2.05B 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$1.99B 10-K · filed 2022-03-01 |
| 2020-09-30 | -$1.92B 10-Q · filed 2020-11-04 |
| 2020-06-30 | -$1.83B 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$1.79B 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$1.70B 10-K · filed 2021-02-25 |
| 2019-09-30 | -$1.65B 10-Q · filed 2019-10-31 |
| 2019-06-30 | -$1.61B 10-Q · filed 2019-08-01 |
| 2019-03-31 | -$1.55B 10-Q · filed 2019-05-02 |
| 2018-12-31 | -$1.47B 10-K · filed 2020-02-27 |
| 2018-09-30 | -$1.40B 10-Q · filed 2018-11-06 |
| 2018-06-30 | -$1.34B 10-Q · filed 2018-08-08 |
| 2018-03-31 | -$1.28B 10-Q · filed 2018-05-04 |
| 2017-12-31 | -$1.22B 10-K · filed 2019-02-27 |
| 2017-09-30 | -$1.15B 10-Q · filed 2017-11-07 |
| 2017-06-30 | -$1.09B 10-Q · filed 2017-08-08 |
| 2017-03-31 | -$1.02B 10-Q · filed 2017-05-09 |
| 2016-12-31 | -$933.98M 10-K · filed 2018-02-27 |
| 2016-09-30 | -$855.28M 10-Q · filed 2016-11-07 |
| 2016-06-30 | -$783.67M 10-Q · filed 2016-08-04 |
| 2016-03-31 | -$712.35M 10-Q · filed 2016-05-05 |
| 2015-12-31 | -$662.59M 10-K · filed 2017-02-28 |
| 2015-09-30 | -$616.80M 10-Q · filed 2015-11-05 |
| 2015-06-30 | -$577.90M 10-Q · filed 2015-08-06 |
| 2015-03-31 | -$538.52M 10-Q · filed 2015-05-07 |
| 2014-12-31 | -$498.14M 10-K · filed 2016-02-29 |
| 2014-09-30 | -$469.78M 10-Q · filed 2014-11-10 |
| 2014-06-30 | -$444.99M 10-Q · filed 2014-08-05 |
| 2014-03-31 | -$423.50M 10-Q · filed 2014-05-06 |
| 2013-12-31 | -$405.67M 10-K · filed 2015-02-26 |
| 2013-09-30 | -$393.62M 10-Q · filed 2013-11-06 |
| 2013-06-30 | -$382.92M 10-Q · filed 2013-08-06 |
| 2013-03-31 | -$373.84M 10-Q · filed 2013-05-07 |
| 2012-12-31 | -$367.72M 10-K · filed 2014-02-27 |
| 2012-09-30 | -$360.91M 10-Q · filed 2012-11-05 |
| 2012-06-30 | -$358.51M 10-Q · filed 2012-08-08 |
| 2012-03-31 | -$353.09M 10-Q · filed 2012-05-08 |
| 2011-12-31 | -$346.87M 10-K · filed 2013-03-12 |
| 2011-09-30 | -$341.57M 10-Q · filed 2011-11-09 |
| 2011-06-30 | -$336.50M 10-Q · filed 2011-08-10 |
| 2010-12-31 | -$324.11M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |